TE21 (EORTC 30983)
A randomised trial of BEP vs Taxol-BEP in histologically proven metastatic germ cell cancer with intermediate prognosis
Can a drug called taxol help to treat men with testicular cancer?
What is this study about?
Most men diagnosed with testicular cancer will be successfully cured. However for some patients treatment is less successful in the long-term. The aim of this trial is to add an extra drug (Taxol) to the standard chemotherapy treatment to see if this helps to treat these patients. The standard chemotherapy for patients in this trial is known as BEP and it uses three drugs, called bleomycin, etoposide and cisplatin. Patients will be randomly allocated to either BEP or to Taxol-BEP.
Type of study
Who is funding the study?
This research is being funded by the European Organisation for Research and Treatment of Cancer (EORTC).
When is it taking place?
This trial has now closed due to poor recruitment and is in follow-up.
Where is it taking place?
Hospitals throughout the UK and Europe.
Who is included?
Patients with intermediate prognosis male germ cell tumours.